Ibogaine consortium gains steam with new bills in MS and OK; Federal psychedelics efforts remain stagnant

Ibogaine advocacy group Americans for Ibogaine is building momentum through new state bills in Mississippi and Oklahoma that aim to enable FDA-aligned ibogaine research for opioid use disorder and related conditions. In Mississippi, the state House voted to advance Senate Bill 2561, using a portion of expected opioid settlement funds to study ibogaine and pursue FDA approval. The newsletter also reports that Oklahoma legislators have pre-filed a bill (HB3834) for state health to partner with a drug developer on ibogaine clinical trials, potentially letting the state share in intellectual property profits if FDA approval is achieved. The newsletter frames federal psychedelics progress as stagnant, citing disappointment among executives and advocates, pressure on the administration to act, and new disclosures about an apparent glut of psychedelic investigational drug applications. It also covers state-level psilocybin policy moves, including New Jersey funding for psilocybin research and Oregon closing a late-night loophole for psilocybin service center operations.